A insuficiência cardíaca congestiva refratária a tratamento clínico tem no transplante cardíaco ortotópico a sua melhor opção cirúrgica. Escassez de doadores, morbidade significativa associada com a terapêutica anti-rejeição, aterosclerose coronária e custos consideráveis associados com o transplante são fatores responsáveis pela sua limitada aplicação. Para os que se encontram na lista para transplante, o período de espera de 6 meses a 1 ano pode levar à deterioração hemodinâmica e expressivo número de mortes. A sobrevida, na lista de espera, pode ser de 46% em 1 ano (1). Afora isso, um significativo número de pacientes tem contra-indicação para transplante, por apresentar hipertensão e resitência pulmonar elevadas. A ventriculectomia parcial esquerda (VPE) (2, 3), restaurando o raio do ventrículo esquerdo e melhorando, assim, a relação massa-volume e o desempenho sistólico, pode propiciar diminuição da pressão e da resistência arterial pulmonar, em alguns pacientes.
Medically refractory heart failure is traditionally managed with cardiac transplantation although some limited success has also been obtained in selected patients with alternative surgical options. Scarce donors, significant morbidity secondary to the antirejection therapy, post-transplantation coronary disease and the high costs of transplantation programs, all together are limiting factors. For those on the waiting list of transplantation the one year mortality may be as high as 46%. Furthermore, a significant number of patients have contraindication to transplantation due to severe pulmonary arterial hypertension and elevated pulmonary vascular resistance. Partial Left Ventriculectomy (PLV) attempts to relieve symptoms of congestive heart failure by reducing left ventricular dimensions and mass and restoring the normal mass-to-volume ratio of the left ventricle. As a consequence, cardiac index and forward ejection fraction increase thus unloading the pulmonary vascular bed. The ultimate result is a decrease in both pulmonary arterial pressure and resistance, in some patients

No abstract

In spite of improvement of ventricular function and quality of life of the survivors, high mortality is a limiting factor. PLV can be indicated as a bridge to heart transplantation in high-PVR patients or if ventricular assist devices or donor hearts are not available.

No abstract

Newer oxygenators with the latest technologies are designed to attenuate the immune response, including lymphopenia, prompted by cardiopulmonary bypass (CPB) in cardiac surgery. We evaluated the effect of CPB, comparing an oxygenator with a venous-arterial shunt and a conventional oxygenator with regard to lymphocyte's early activation and apoptosis induction and its implications in post-CPB lymphopenia. Patients undergoing coronary artery bypass graft surgery with CPB, using either a conventional oxygenator or one with a venous-arterial shunt, had blood samples drawn at anesthetic induction (baseline); the beginning and end of the CPB; and at 6, 12, and 24 hours after surgery. Analysis by flow cytometry was undertaken to assess the expression of lymphocyte surface markers (CD3+, CD25+, CD26+, CD69+) and apoptosis (annexin V). Twenty patients were studied; 10 used a conventional oxygenator, and 10 used an oxygenator with venous-arterial shunt. Postoperative lymphopenia (50% decrease), 35% increased expression of CD69+, and 56% decrease in annexin V were significant comparing baseline to 24 hour value, similarly in both groups. Early activation (expression of CD69+) and degree of apoptosis (expression of annexin V) of lymphocytes after CBP in cardiac surgery was similarly observed in both types of oxygenators. The observed lymphopenia after CPB does not appear to be secondary to apoptosis.